# Effects of Vitamin D Supplementation on Cardiovascular Outcomes in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis

**Authors:** Ayesha Saleem, Suraj S Padakanti, Mohsin Hajjaj, Muhammad Shariq Akram, Sowmya Manjari Siddenthi, Versha Kumari, Fenil Gandhi, Lakshmi Tejaswi Sakhamuri, Christopher Belletieri, Pavan K Erravelli, Ali Usama

PMC · DOI: 10.7759/cureus.87378 · Cureus · 2025-07-06

## TL;DR

This study reviews whether vitamin D helps reduce heart problems in patients with chronic kidney disease.

## Contribution

A meta-analysis of randomized trials to assess vitamin D's cardiovascular effects in chronic kidney disease patients.

## Key findings

- Vitamin D reduced risk of adverse cardiovascular events (RR 0.39; 95% CI 0.22 to 0.69).
- No significant changes in LVEF, LVMI, SBP, or DBP with vitamin D supplementation.
- Results suggest need for larger trials to confirm potential benefits.

## Abstract

Vitamin D supplementation may have beneficial effects on cardiovascular outcomes in patients with chronic kidney disease (CKD), but the underlying data are conflicting. We conducted a meta-analysis to investigate the effect of vitamin D on cardiovascular outcomes in patients with CKD.

We searched MEDLINE (via PubMed), the Cochrane Library, Scopus, and ClinicalTrials.gov from inception to 16 March 2024 for all randomized controlled trials (RCTs) assessing vitamin D supplementation in patients with CKD and reporting cardiovascular outcomes. Our primary outcomes were the incidence of adverse cardiovascular events and the change in left ventricular ejection fraction (LVEF) and left ventricular mass index (LVMI). Our secondary outcomes were the change in systolic blood pressure (SBP) and diastolic blood pressure (DBP). Data were pooled using risk ratio (RR) and mean difference as the effect measures.

A total of 11 RCTs were included in our review. Vitamin D supplementation reduced the risk of adverse cardiovascular events in patients with CKD (RR 0.39; 95% CI 0.22 to 0.69; I2=0). There was no significant difference in LVEF, LVMI, SBP, and DBP between the vitamin D and control groups.

Vitamin D supplementation does not affect adverse cardiovascular events, LVEF, LVMI, SBP, and DBP. Further large-scale RCTs and mechanistic studies are needed to understand the potential benefits of vitamin D supplementation in this patient population.

## Linked entities

- **Diseases:** chronic kidney disease (MONDO:0005300)

## Full-text entities

- **Diseases:** CKD (MESH:D051436), left ventricular mass (MESH:D018487)
- **Chemicals:** Vitamin D (MESH:D014807)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12325759/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12325759/full.md

## References

28 references — full list in the complete paper: https://tomesphere.com/paper/PMC12325759/full.md

---
Source: https://tomesphere.com/paper/PMC12325759